[目的]评价西妥昔单抗联合化疗治疗大肠癌肝转移的近期疗效和不良反应。[方法]35例大肠癌肝转移患者采用西妥昔单抗、伊立替康、亚叶酸钙、氟尿嘧啶联合化疗,2周重复1次。4周期化疗后评价疗效及不良反应。[结果]全组35例均可评价疗效,完全缓解(CR)2例,部分缓解(PR)9例,疾病稳定(SD)18例,疾病进展(PD)6例,有效率(RR)为31.43%,疾病控制率(DCR)为82.86%;中位无进展生存时间(PFS)为15.2个月,中位总生存时间(OS)为50.9个月。不良反应主要表现为痤疮样皮疹、腹泻和血液学毒性。[结论]西妥昔单抗联合FOLFIRI方案治疗大肠癌肝转移疗效肯定,其不良反应可以耐受。 [Objective] To evaluate the short-term curative effect and adverse reaction of cetuximab combined with chemotherapy for liver metastasis of colorectal cancer. [Method] 35 patients with liver metastasis of colorectal cancer were treated with cetuximab, irinotecan, leucovorin and fluorouracil combined with chemotherapy and repeated once every 2 weeks. After 4 cycles of chemotherapy to evaluate the efficacy and adverse reactions. [Results] All of the 35 patients could evaluate the curative effect. There were 2 cases of complete remission (CR), 9 cases of partial remission (PR), 18 cases of stable disease (SD) and 6 cases of disease progression (PD). The effective rate 31.43%, and the disease control rate (DCR) was 82.86%. The median progression-free survival time (PFS) was 15.2 months and the median overall survival time (OS) was 50.9 months. Adverse reactions mainly manifested as acne-like rash, diarrhea and hematological toxicity. [Conclusion] The cetuximab combined with FOLFIRI regimen is effective in treating liver metastasis of colorectal cancer, and its side effects can be tolerated.